Related Topics News -

     
 Title only   |   Print    Next page > 
     
瑞博生物核心產品VORTOSIRAN向EMA遞交針對靜脈血栓栓塞症防治2b期臨床申請

2026-05-11T  
瑞博生物與勃林格殷格翰MASH合作達成第三個關鍵里程碑

2026-05-06T  
瑞博生物核心產品Vortosiran向歐洲遞交針對SPAF適應症臨床試驗申請

2026-04-14T  
《業績》瑞博生物全年虧損擴至2.78億人民幣

2026-03-26T  
《大行》花旗首予瑞博生物「買入」評級 目標價102元

2026-03-05T  
瑞博生物-BRBD7022注射液將啟動III期臨床試驗

2026-03-02T  
《大行》中金首次覆蓋瑞博生物予「跑贏行業」評級 小核酸藥物開發全球領軍者

2026-02-20T  
瑞博生物向Madrigal授出全球授權 收6,000萬美元首付款

2026-02-11T  
瑞博生物超額配股權悉數行使 額外籌2.62億元

2026-02-06T  
瑞博生物自主研發管理血脂紊亂藥物獲批進入II期臨床

2026-01-23T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.